| answer text |
<p>The Government is committed to ensuring that patients have access to new and effective
treatments, including those which may extend life, on terms that represent value to
the National Health Service and the taxpayer.</p><p> </p><p> </p><p> </p><p>The National
Institute for Health and Care Excellence (NICE) is the independent body responsible
for providing advice to the NHS on the clinical and cost-effectiveness of health technologies.
NHS commissioners are legally required to fund treatments recommended by NICE technology
appraisal guidance, ensuring consistent access to clinically and cost effective drugs
across England. NICE has introduced greater flexibility in the appraisal of effective
drugs for patients at the end of their lives, which has helped to secure patient access
to a number of potentially life-extending drugs.</p><p> </p><p> </p><p> </p><p>We
are commissioning an external review of the pathways for the development, assessment,
and adoption of innovative medicines and medical technology. This review will consider
how to speed up access for NHS patients to cost-effective new diagnostics, medicines
and devices.</p><p> </p><p> </p><p> </p><p><strong> </strong></p><p> </p><p><strong>
</strong></p><p> </p>
|
|
